Aug 10, 2017 11:52 am UTC| Business
Revenue• $58.5 million for Q2 2017• $122.9 million for the six months 2017Adjusted EBITDA• $27.1 million for Q2 2017• $64.5 million for the six months 2017Quarterly dividend of $0.05 per share – consistently paid since...
Aug 10, 2017 11:32 am UTC| Business
Dublin, Aug. 10, 2017 -- The "mRNA Vaccines Therapeutics 2017: an Industry Analysis of Technologies, Pipelines, Stakeholders and Deals" report has been added to Research and Markets' offering. ...
Aug 10, 2017 11:30 am UTC| Business
SOUTHFIELD, Mich., Aug. 10, 2017 -- Stefanini, a $1B global IT provider, moved its corporate office in Southfield to a new address: an open-space concept which is more aligned with Stefanini’s values. The new office...
Aug 10, 2017 11:30 am UTC| Business
Based on pre-set hurdles of Overall Response Rate (ORR) the DSMB recommends continued enrollment in the TGR-1202 + TG-1101 (“U2”) arm and no further enrollment into the single agent TGR-1202 arm As set forth in the...
Evogene Reports Second Quarter 2017 Financial Results
Aug 10, 2017 11:30 am UTC| Business
REHOVOT, Israel, Aug. 10, 2017 -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics, announced today its financial results for the second quarter ended June...
BlueLinx Announces Second-Quarter Results
Aug 10, 2017 11:30 am UTC| Business
– Net Income of $3.2 Million; Best Second Quarter Since 2008 –– Adjusted EBITDA of $12.8 Million; Best Second Quarter Since 2008 – – Gross Margin of 12.8%, up 150 Basis Points From Q2 2016 – – Debt Principal Reduction...
KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial
Aug 10, 2017 11:30 am UTC| Business
Phase I Study Results Demonstrated Early Peak Exposure to d-Methylphenidate followed by Sustained Duration in both Single and Multiple Dose Settings CORALVILLE, Iowa, Aug. 10, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a...